|2.53||-0.0100||-0.39%||Vol 122.53K||1Y Perf -17.26%|
|Jan 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||-||Analyst Rating||— 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★ 47.44|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Market Cap||195.34M||Earnings Rating||Neutral|
|Price Range Ratio 52W %||27.80||Earnings Date||11th Nov 2020|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||99.19K|
|Avg. Monthly Volume||163.14K|
|Avg. Quarterly Volume||148.41K|
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) stock closed at 2.54 per share at the end of the most recent trading day (a -0.78% change compared to the prior day closing price) with a volume of 134.66K shares and market capitalization of 195.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5 people. Nymox Pharmaceutical Corporation CEO is Paul Averback.
The one-year performance of Nymox Pharmaceutical Corporation stock is -17.26%, while year-to-date (YTD) performance is 2.42%. NYMX stock has a five-year performance of 15.45%. Its 52-week range is between 1.66 and 4.79, which gives NYMX stock a 52-week price range ratio of 27.80%
Nymox Pharmaceutical Corporation currently has a PE ratio of -15.00, a price-to-book (PB) ratio of 54.23, a price-to-sale (PS) ratio of 41 385.20, a price to cashflow ratio of 76.80, a PEG ratio of 2.32, a ROA of -180.11%, a ROC of -253.02% and a ROE of -249.91%. The company’s profit margin is -%, its EBITDA margin is -38 506.50%, and its revenue ttm is $5.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Nymox Pharmaceutical Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Nymox Pharmaceutical Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Nymox Pharmaceutical Corporation is — (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Nymox Pharmaceutical Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Nymox Pharmaceutical Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Nymox Pharmaceutical Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.67, ATR14 : 0.37, CCI20 : 27.53, Chaikin Money Flow : 73.44, MACD : 0.09, Money Flow Index : 60.96, ROC : 0.40, RSI : 49.94, STOCH (14,3) : 89.34, STOCH RSI : 0.00, UO : 76.60, Williams %R : -10.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Nymox Pharmaceutical Corporation in the last 12-months were:
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.